Cardinal Health enters fiscal 2027 with strong momentum across pharmaceutical distribution, specialty solutions and growth businesses. The company reported fourth-quarter fiscal 2026 pharmaceutical and specialty solutions revenue of $58.8 billion, up 6%, with segment profit rising 21% to $645 million. Management expects fiscal 2027 pharma revenue growth of 3-5% and segment profit growth of 8-11%, while specialty revenues are projected to grow double digits. The company also secured two additional gene-therapy commercialization agreements, bringing its exclusive coverage to nearly half of the cell-and-gene market. However, Inflation Reduction Act pricing changes, low growth in Global Medical Products and Distribution, and heavy capital expenditures are expected to constrain performance.
Veracyte Inc
West Pharmaceutical Services IncCardinal Health IncStrong pharma revenue growth and gene-therapy agreements boost outlook.
Globus Medical